Literature DB >> 28866101

MiR-542-3p exerts tumor suppressive functions in non-small cell lung cancer cells by upregulating FTSJ2.

Bin Liu1, Jing Li2, Min Zheng1, Jun Ge1, Juan Li1, Ping Yu3.   

Abstract

AIMS: Up-regulation or down-regulation of microRNAs (miRNAs) has been found in non-small cell lung cancer (NSCLC). However, the role and mechanism of regulation of miR-542-3p in NSCLC is still unclear. This study aimed at investigating the primary biological function of miR-542-3p and FTSJ2 in NSCLC tumorigenesis and the correlation of miR-542-3p and FTSJ2 in NSCLC. MAIN
METHODS: Our present results showed that miR-542-3p was down-regulated in NSCLC tissues and cancer cells. Overexpression of miR-542-3p inhibited cell proliferation, cell migration, cell cycle, EMT process and tumor growth in vitro, and induced cell apoptosis by MTT assay, colony formation assay, transwell migration assay, flow cytometry assay, RT-qPCR assay, western blot experiment and vivo model assay; miR-542-3p directly bound to the 3'UTR of FTSJ2 and upregulated FTSJ2 both mRNA and protein level by EGFP reporter assay, RT-qPCR and western blot analysis in NSCLC cells. FTSJ2 also reduced the aggressiveness of NSCLC cells. KEY
FINDINGS: In short, miR-542-3p functions as a suppressor gene by targeting and upregulating FTSJ2, thus inhibiting the malignancy of NSCLC cells. SIGNIFICANCE: According to the results, miRNA-542-3p and its targeted FTSJ2 may be indispensable as a predictive biomarker of the response to the treatment in patients with NSCLC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EMT; FTSJ2; NSCLC; Up-regulated; miR-542-3p

Mesh:

Substances:

Year:  2017        PMID: 28866101     DOI: 10.1016/j.lfs.2017.08.018

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

Review 1.  Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer.

Authors:  Matthew Saldana; Kacey VanderVorst; Anastasia L Berg; Hyun Lee; Kermit L Carraway
Journal:  Endocr Relat Cancer       Date:  2019-01-01       Impact factor: 5.678

2.  Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.

Authors:  Zhen Li; Jian-Ni Yao; Wen-Ting Huang; Rong-Quan He; Jie Ma; Gang Chen; Qing-Jun Wei
Journal:  Mol Med Rep       Date:  2018-12-13       Impact factor: 2.952

3.  Long Non Coding RNA SNHG16 Facilitates Proliferation, Migration, Invasion and Autophagy of Neuroblastoma Cells via Sponging miR-542-3p and Upregulating ATG5 Expression.

Authors:  Yi Wen; Xiaohui Gong; Yubin Dong; Chenghe Tang
Journal:  Onco Targets Ther       Date:  2020-01-10       Impact factor: 4.147

Review 4.  Human Mitoribosome Biogenesis and Its Emerging Links to Disease.

Authors:  Maria Isabel G Lopez Sanchez; Annika Krüger; Dmitrii I Shiriaev; Yong Liu; Joanna Rorbach
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

Review 5.  Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.

Authors:  Sarah Sayed Hassanein; Sherif Abdelaziz Ibrahim; Ahmed Lotfy Abdel-Mawgood
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

6.  Analysis of differential expression profile of miRNA in peripheral blood of patients with lung cancer.

Authors:  Qingfang He; Yirong Fang; Feng Lu; Jin Pan; Lixin Wang; Weiwei Gong; Fangrong Fei; Jingjie Cui; Jieming Zhong; Ruying Hu; Mingbin Liang; Le Fang; Hao Wang; Min Yu; Zuo-Feng Zhang
Journal:  J Clin Lab Anal       Date:  2019-09-20       Impact factor: 2.352

7.  Downregulation of miR-542-3p promotes osteogenic transition of vascular smooth muscle cells in the aging rat by targeting BMP7.

Authors:  Huan Liu; Hongwei Wang; Sijin Yang; Dehui Qian
Journal:  Hum Genomics       Date:  2019-12-11       Impact factor: 4.639

8.  A novel risk signature with 6 RNA binding proteins for prognosis prediction in patients with glioblastoma.

Authors:  Qian-Rong Huang; Jian-Wen Li; Xin-Bin Pan
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.